Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

The present invention describes a pharmaceutical composition that includes a novel molecule with neuroprotective activity, to inhibit the neuroadaptations induced by opioids (tolerance and hyperalgesia) that lead to the successive escalation of its doses in the treatment of pain. In this way, it increases its analgesic efficacy in normal conditions and in neural damage, since this favors the appearance of tolerance/hyperalgesia and resistance to opioid treatment. Likewise, reduce the spontaneous signs of withdrawal associated with its withdrawal and consequently physical dependence and possible addiction. In addition, it describes a method for the treatment of pain with a neuropathic component that is supported by drug interaction and safety studies that show its synergy for the mechanical antihypernociceptive effect.

The present invention describes a pharmaceutical composition that includes a novel molecule with neuroprotective activity, to inhibit the neuroadaptations induced by opioids (tolerance and hyperalgesia) that lead to the successive escalation of its doses in the treatment of pain. In this way, it increases its analgesic efficacy in normal conditions and in neural damage, since this favors the appearance of tolerance/hyperalgesia and resistance to opioid treatment. Likewise, reduce the spontaneous signs of withdrawal associated with its withdrawal and consequently physical dependence and possible addiction. In addition, it describes a method for the treatment of pain with a neuropathic component that is supported by drug interaction and safety studies that show its synergy for the mechanical antihypernociceptive effect.

The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABA.sub.A agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABA.sub.A receptor in dorsal root ganglion neurons in the subject using a vector.

The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABA.sub.A agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABA.sub.A receptor in dorsal root ganglion neurons in the subject using a vector.

The present disclosure discloses a new use of desloratadine (DLT) and pharmaceutically acceptable salts thereof in preparing a drug for treating a neurodegenerative disease related to motor dysfunction. The present disclosure shows, through a large number of experimental tests, that desloratadine and the pharmaceutically acceptable salts thereof can improve the state of motor dysfunction in an SOD1-G93A model mouse in the behavioral experimental tests of Rotarod experimental test, gait monitoring experimental test and cage experimental test, and that desloratadine and the pharmaceutically acceptable salts thereof can effectively delay the onset time and prolong the survival cycle of the SOD1-G93A model mouse, and therefore, desloratadine and the pharmaceutically acceptable salts thereof can be used to treat neurodegenerative diseases related to motor dysfunction, including amyotrophic lateral sclerosis.

The present disclosure discloses a new use of desloratadine (DLT) and pharmaceutically acceptable salts thereof in preparing a drug for treating a neurodegenerative disease related to motor dysfunction. The present disclosure shows, through a large number of experimental tests, that desloratadine and the pharmaceutically acceptable salts thereof can improve the state of motor dysfunction in an SOD1-G93A model mouse in the behavioral experimental tests of Rotarod experimental test, gait monitoring experimental test and cage experimental test, and that desloratadine and the pharmaceutically acceptable salts thereof can effectively delay the onset time and prolong the survival cycle of the SOD1-G93A model mouse, and therefore, desloratadine and the pharmaceutically acceptable salts thereof can be used to treat neurodegenerative diseases related to motor dysfunction, including amyotrophic lateral sclerosis.

The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.